A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors

Marcus Schmidt1, Birte Hellwig6, Seddik Hammad7, Amnah Othman7, Miriam Lohr6, Zonglin Chen1, Daniel Boehm1, Susanne Gebhard1, Ilka Petry1, Antje Lebrecht1, Cristina Cadenas7, Rosemarie Marchan7, Joanna D. Stewart7, Christine Solbach1, Lars Holmberg8,9,12, Karolina Edlund10, Hanna Göransson Kultima11, Achim Rody13, Anders Berglund8,14, Mats Lambe7,8, Anders Isaksson11, Johan Bottling10, Thomas Karl15, Volkmar Müller16, Aslihan Gerhold-Ay2, Christina Cotarelo3, Martin Sebastian4, Ralf Kronewett17, Hans Bojar18, Hans-Anton Lehr19, Ugur Sahin5, Heinz Koebel1, Mathias Gehrmann20, Patrick Micke10, Jörg Rahnenführer6, and Jan G. Hengstler7

Abstract

**Purpose:** Although the central role of the immune system for tumor prognosis is generally accepted, a single robust marker is not yet available.

**Experimental Design:** On the basis of receiver operating characteristic analyses, robust markers were identified from a 60-gene B cell–derived metagene and analyzed in gene expression profiles of 1,810 breast cancer; 1,056 non–small cell lung carcinoma (NSCLC); 513 colorectal; and 426 ovarian cancer patients. Protein and RNA levels were examined in paraffin-embedded tissue of 330 breast cancer patients. The cell types were identified with immunohistochemical costaining and confocal fluorescence microscopy.

**Results:** We identified immunoglobulin κ C (IGKC) which as a single marker is similarly predictive and prognostic as the entire B-cell metagene. IGKC was consistently associated with metastasis-free survival across different molecular subtypes in node-negative breast cancer (n = 965) and predicted response to anthracycline-based neoadjuvant chemotherapy (n = 845; P < 0.001). In addition, IGKC gene expression was prognostic in NSCLC and colorectal cancer. No association was observed in ovarian cancer. IGKC protein expression was significantly associated with survival in paraffin-embedded tissues of 330 breast cancer patients. Tumor-infiltrating plasma cells were identified as the source of IGKC expression.

**Conclusion:** Our findings provide IGKC as a novel diagnostic marker for risk stratification in human cancer and support concepts to exploit the humoral immune response for anticancer therapy. It could be validated in several independent cohorts and carried out similarly well in RNA from fresh frozen as well as from paraffin tissue and on protein level by immunostaining. Clin Cancer Res; 18(9); 2695–703. ©2012 AACR.

**Authors’ Affiliations:** Departments of 1Obstetrics and Gynecology, 2Medical Biometry, 3Pathology, and 4Hematology and Oncology, University Hospital; 5TRON-Translational Oncology at the Medical University Mainz, Mainz; 6Department of Statistics, Technical University, Dortmund; 7Leibniz Research Centre for Working Environment and Human Factors (IfADo) at Dortmund TU, Germany; 8Regional Oncology Center; 9Department of Surgical Sciences; 10Department of Genetics and Pathology; 11Department of Pathology, University of Lausanne, Lausanne, Switzerland; and 20Bayer Clinical Biometry, 3Pathology, and 4Hematology and Oncology, University Hospital; 5TRON-Translational Oncology at the Medical University Mainz, Mainz, Langenbeckstr. 1, Mainz 55131, Germany. Phone: 49-613-172-683; Fax: 49-613-175-673; E-mail: marcus.schmidt@unimedizin-mainz.de; Jörg Rahnenführer, Department of Statistics, Technical University, Dortmund 44221, Germany. Phone: 49-231-7553-121; Fax: 49-231-7555-303; E-mail: rahnenfuehrer@statistik.tu-dortmund.de; and Jan G. Hengstler, Leibniz Research Centre for Working Environment and Human Factors (IfADo) at Dortmund TU, Ardenstr. 67, Dortmund 44139, Germany. Phone: 49-231-1084-348/349; Fax: 49–231-1084-403; E-mail: hengstler@ifado.de

**Note:** Supplementary data for this article are available at Clinical Cancer Research Online (http://cancerres.aacrjournals.org/).


**Parts of this study were presented at the San Antonio Breast Cancer Symposium 2009 and at the Annual Meeting of the American Society of Clinical Oncology 2010.**

The study contains parts of the doctoral theses of A. Gerhold-Ay and Z. Chen.

**Corresponding Authors:** Marcus Schmidt, Department of Obstetrics and Gynecology, University Hospital Mainz, Langenbeckstr. 1, Mainz 55131, Germany, Phone: 49-613-1172-689; Fax: 49-613-1175-673; E-mail: marcus.schmidt@unimedizin-mainz.de; Jörg Rahnenführer, Department of Statistics, Technical University, Dortmund 44221, Germany. Phone: 49-231-7553-121; Fax: 49-231-7555-303; E-mail: rahnenfuehrer@statistik.tu-dortmund.de; and Jan G. Hengstler, Leibniz Research Centre for Working Environment and Human Factors (IfADo) at Dortmund TU, Ardenstr. 67, Dortmund 44139, Germany. Phone: 49-231-1084-348/349; Fax: 49–231-1084-403; E-mail: hengstler@ifado.de

**doi:** 10.1158/1078-0432.CCR-11-2210

©2012 American Association for Cancer Research.
Introduction

It has become evident that the immune response in the tumor environment plays a pivotal role in all stages of carcinogenesis and in different contexts may promote or inhibit tumor progression (1–3). In human cancer, this concept is supported by the observation that the presence of specific immune cells can be linked to different clinical outcomes. For instance, high numbers of T lymphocytes were associated with good prognosis in many human cancer types (4, 5). Also, immune modulatory chemokines were related to the natural course of cancer as well as to response to therapy (6, 7).

With introduction of high resolution gene expression arrays, it has become evident that a lot of prognostic gene signatures consist of immune markers (8–11). Particularly in breast cancer, several prognostic and predictive gene signatures reflect the individual immune response, independent from traditional markers like hormone receptor status or Ki-67 proliferation index (12–14). To systematically distinguish between T and B cell–related effects on the natural course of breast cancer, we previously showed that the humoral immune system, as summarized in a 60-gene B-cell signature, had a strong protective impact on metastasis-free survival (MFI) in node-negative breast cancer patients (15). However, analysis of a 60-gene signature by real-time PCR (RT-PCR) is costly and relatively labor intensive. To improve the clinical applicability, we studied whether the influence of the B-cell metagene on prognosis can be narrowed down to a single gene. We report that the prognostic information provided by both mRNA and protein levels of immunoglobulin κ C (IGKC) was comparable with that of the 60-gene B-cell metagene. Next, we identified the cellular source of IGKC and evaluated this host-dependent signature in other common cancer types. Finally, to translate the findings to robust analytic tools for clinical diagnostics on routinely archived tissue, immunohistochemistry was applied.

Patients and Methods

Patients

Our analysis includes gene array data from 1,810 breast cancer patients (965 node negative, without chemotherapy and 845 with anthracycline-based chemotherapy), 1,056 non–small cell lung carcinoma (NSCLC), 513 colorectal, and 426 ovarian cancer patients. In addition, paraffin-embedded tissue blocks of 330 node-negative breast cancer patients were analyzed (detailed description, Supplementary Methods).

Gene expression analysis and immunostaining

HG-U133A arrays were used to analyze Uppsala lung cancer (n = 196) cohorts (Supplementary Table S1). All other gene array data are publicly available (Supplementary Methods). IGKC mRNA levels in formalin-fixed, paraffin-embedded (FFPE) tissue were quantified by quantitative RT-PCR (qRT-PCR). For both immunohistochemistry and confocal-fluorescence microscopy, antibodies against MUM1/IRF4, CD20, pan-cytokeratin, or immunoglobulin G (IgG) and IGKC were used as previously described (details, Supplementary Methods).

Statistical analysis

Survival was analyzed by univariate and multivariate Cox models and visualized by Kaplan–Meier plots. The Brier score was used to evaluate the ability to predict survival. Meta-analyses were conducted by fixed and random effect models and visualized with forest plots (details, Supplementary Methods).

Results

IGKC is a representative marker of the B-cell gene signature

To condense the previously described breast cancer B-cell signature (15) that consists of 60 genes, we analyzed microarray data from our own breast cancer cohort (Mainz) and 2 independent cohorts [Rotterdam (19); Transbig (16, 17)]. The bioinformatic strategy was based on the optimal combination of 2 criteria (Fig. 1): (i) the best average correlation of each of the 60 genes with all other members of the B-cell metagene as a measure of representativeness, and (ii) the largest area under the receiver operating characteristic curve, as a measure of the ability of each individual gene to discriminate between patients with and without metastasis during a 5-year follow-up period. Using these 2 criteria, IGKC was identified as one of the genes with the best average correlation and largest area under the curve (AUC; Fig. 1) and also showed a wide dynamic range with a unimodal distribution (Supplementary Fig. S1). The results obtained by microarrays were confirmed with qRT-PCR in archived FFPE tissue from the Mainz cohort. IGKC mRNA levels

Translational Relevance

This study reports that immunoglobulin κ C (IGKC) RNA levels robustly define prognosis in a comprehensive analysis of available breast cancer data sets and predict response to neoadjuvant anthracycline–based therapy. In addition, IGKC maintains its prognostic relevance also in non–small cell lung and colorectal cancer, suggesting a global mechanism in the biology of adenocarcinomas. Using real-time PCR and immunohistochemistry in formalin-fixed, paraffin-embedded (FFPE) tissue, we could validate the prognostic impact of IGKC. Furthermore, using confocal microscopy, we identified tumor-infiltrating plasmablasts and plasma cells as the source of IGKC expression. This study has major clinical implications: (i) IGKC as a prognostic and predictive marker that lends itself to systematic testing in FFPE tissue samples allows an improved prediction of prognosis and response to chemotherapy, and (ii) the protective effects of this naturally occurring humoral immune response support the concept of immunotherapy.
determined by qRT-PCR, correlated very well with the levels measured by gene array in fresh-frozen samples of the same tumors (Fig. 2A) and similarly, IGKC mRNA levels in paraffin-embedded tissue showed a significant association with MFI both in univariate and multivariate analyses (Table 3; Kaplan–Meier plot: Fig. 2B).

**IGKC is associated with better prognosis in breast cancer**

To further validate the prognostic impact of IGKC, we analyzed mRNA expression as a single marker in 5 publicly accessible gene array data sets of node-negative breast cancer patients who did not receive chemotherapy: the Mainz (15), Rotterdam (19), Transbig (16, 17), Yu (18), and NKI (20, 21) cohorts. The meta-analysis revealed a highly significant association of IGKC RNA levels with better prognosis ($P < 0.0001$, Fig. 3). The expression of IGKC was further analyzed in the 3 molecularly and biologically different subtypes of breast cancer (14): (i) estrogen receptor (ER) status positive and HER2 status negative, (ii) ER status negative, and (iii) HER2 status positive and ER status positive or negative carcinomas. High IGKC expression correlated with good prognosis in all subgroups with a particularly strong association in the HER2-positive subgroup (Fig. 3). The univariate (Table 1) and multivariate Cox regression models (Table 2) adjusted to established clinical factors (Supplementary Fig. S2) confirmed the association of IGKC with MFI (Table 1, Figure 2).
**A** Breast cancer, all patients

<table>
<thead>
<tr>
<th>Study</th>
<th>n</th>
<th>HR</th>
<th>(95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mainz</td>
<td>200</td>
<td>0.81</td>
<td>(0.66–1.00)</td>
<td>0.001</td>
</tr>
<tr>
<td>Rotterdam</td>
<td>286</td>
<td>0.80</td>
<td>(0.71–0.89)</td>
<td>0.001</td>
</tr>
<tr>
<td>Transbig</td>
<td>280</td>
<td>0.85</td>
<td>(0.72–0.99)</td>
<td>0.001</td>
</tr>
<tr>
<td>NKI</td>
<td>141</td>
<td>0.86</td>
<td>(0.72–0.99)</td>
<td>0.001</td>
</tr>
<tr>
<td>Yu</td>
<td>58</td>
<td>0.81</td>
<td>(0.66–1.00)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

**B** ER+/HER2−

<table>
<thead>
<tr>
<th>Study</th>
<th>n</th>
<th>HR</th>
<th>(95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mainz</td>
<td>158</td>
<td>0.75</td>
<td>(0.58–0.96)</td>
<td>0.001</td>
</tr>
<tr>
<td>Rotterdam</td>
<td>178</td>
<td>0.81</td>
<td>(0.69–0.94)</td>
<td>0.001</td>
</tr>
<tr>
<td>Transbig</td>
<td>186</td>
<td>0.86</td>
<td>(0.69–1.06)</td>
<td>0.001</td>
</tr>
<tr>
<td>NKI</td>
<td>88</td>
<td>0.87</td>
<td>(0.66–1.16)</td>
<td>0.001</td>
</tr>
<tr>
<td>Yu</td>
<td>0</td>
<td>0.82</td>
<td>(0.73–0.91)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

**C** ER+/HER2−

<table>
<thead>
<tr>
<th>Study</th>
<th>n</th>
<th>HR</th>
<th>(95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mainz</td>
<td>23</td>
<td>0.81</td>
<td>(0.66–0.96)</td>
<td>0.001</td>
</tr>
<tr>
<td>Rotterdam</td>
<td>58</td>
<td>0.80</td>
<td>(0.60–1.06)</td>
<td>0.001</td>
</tr>
<tr>
<td>Transbig</td>
<td>59</td>
<td>0.84</td>
<td>(0.61–1.18)</td>
<td>0.001</td>
</tr>
<tr>
<td>NKI</td>
<td>32</td>
<td>0.72</td>
<td>(0.51–1.02)</td>
<td>0.001</td>
</tr>
<tr>
<td>Yu</td>
<td>48</td>
<td>0.72</td>
<td>(0.51–1.02)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

**D** HER2+

<table>
<thead>
<tr>
<th>Study</th>
<th>n</th>
<th>HR</th>
<th>(95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mainz</td>
<td>19</td>
<td>0.60</td>
<td>(0.29–1.25)</td>
<td>0.001</td>
</tr>
<tr>
<td>Rotterdam</td>
<td>50</td>
<td>0.60</td>
<td>(0.30–1.39)</td>
<td>0.001</td>
</tr>
<tr>
<td>Transbig</td>
<td>35</td>
<td>0.72</td>
<td>(0.47–1.10)</td>
<td>0.001</td>
</tr>
<tr>
<td>NKI</td>
<td>21</td>
<td>0.62</td>
<td>(0.24–1.63)</td>
<td>0.001</td>
</tr>
<tr>
<td>Yu</td>
<td>10</td>
<td>0.62</td>
<td>(0.24–1.63)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

**E** Lung cancer (univariate)

<table>
<thead>
<tr>
<th>Study</th>
<th>n</th>
<th>HR</th>
<th>(95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jacob-00182</td>
<td>448</td>
<td>0.81</td>
<td>(0.75–0.87)</td>
<td>0.001</td>
</tr>
<tr>
<td>GSE14814</td>
<td>90</td>
<td>1.02</td>
<td>(0.74–1.42)</td>
<td>0.001</td>
</tr>
<tr>
<td>Uppsala</td>
<td>196</td>
<td>0.91</td>
<td>(0.79–1.05)</td>
<td>0.001</td>
</tr>
<tr>
<td>GSE4573</td>
<td>129</td>
<td>0.96</td>
<td>(0.84–1.11)</td>
<td>0.001</td>
</tr>
<tr>
<td>GSE3141</td>
<td>111</td>
<td>1.03</td>
<td>(0.84–1.25)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

**F** Lung cancer (adjusted to the proliferation gene UBE2C)

<table>
<thead>
<tr>
<th>Study</th>
<th>n</th>
<th>HR</th>
<th>(95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jacob-00182</td>
<td>448</td>
<td>0.92</td>
<td>(0.85–0.98)</td>
<td>0.001</td>
</tr>
<tr>
<td>GSE14814</td>
<td>90</td>
<td>1.02</td>
<td>(0.76–1.02)</td>
<td>0.001</td>
</tr>
<tr>
<td>Uppsala</td>
<td>196</td>
<td>0.91</td>
<td>(0.79–1.05)</td>
<td>0.001</td>
</tr>
<tr>
<td>GSE4573</td>
<td>129</td>
<td>0.90</td>
<td>(0.85–1.13)</td>
<td>0.001</td>
</tr>
<tr>
<td>GSE3141</td>
<td>111</td>
<td>1.04</td>
<td>(0.85–1.28)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Figure 3. IGKC is associated with better prognosis in node-negative breast cancer and NSCLC. The meta-analysis shows the influence of IGKC on metastasis-free survival in 5 cohorts (Mainz, Rotterdam, Transbig, NKI, and Yu). Data are given for all patients (A) as well as for the 3 breast cancer subgroups according to Desmedt (14), namely ER positive and HER2 negative (B), ER negative and HER2 negative (C), as well as HER2 positive and ER positive or negative (D) patients. In all cohorts, high IGKC is associated with a trend toward better prognosis resulting in a highly significant association in the meta-analysis using the fixed as well as the random effects models. The Yu cohort contains only ER-negative patients and only 1 event in the HER2-positive group and was excluded from the analyses in B and D. IGKC expression is also prognostic in NSCLC either in the univariate Cox model (E) or in the model adjusted to the proliferation marker UBE2C. n, number of patients; P, P value of the fixed effect model.

Supplementary Table S2), disease-free survival (Supplementary Table S3A) and overall survival (OS; Supplementary Table S3B). For further illustration, IGKC gene expression was dichotomized at the median, and Kaplan–Meier curves were plotted (Supplementary Fig. S3). IGKC correlated with recently published biological signatures (15), the B-cell metagene, and to a lesser degree, with the T-cell metagene (15). In addition, there was a weak inverse correlation with the ER metagene but not with the proliferation metagene (Supplementary Fig. S4 and S5). Brier score analysis showed that IGKC alone has a similar predictive power as the complete 60-gene-based B-cell signature (Supplementary Fig. S6).

**IGKC predicts response to anthracycline-based chemotherapy**

In addition to the prediction of survival, IGKC expression levels were evaluated with regard to response to cytostatic drugs. We selected all published gene array data of breast cancer patients who had received anthracycline-based chemotherapy. We selected all published gene array data of breast cancer patients who had received anthracycline-based chemotherapy (Fig. 4). High IGKC expression was associated with complete response (CR) in a meta-analysis that included 7 cohorts (n = 845; P < 0.0001, Fig. 4). Analysis of the subgroups according to Desmedt (14) showed that IGKC is predictive for response in the ER+/HER2− and in the HER2+ subgroups but not in the ER+/HER2+ subgroups. In particular, the association with CR...
was pronounced for the ER-negative patients \( (P < 0.0001, \text{ Supplementary Fig. S7A}) \). In multivariate analyses, the association of IGKC with CR was independent of progesterone receptor (PR), HER2, proliferation status (represented by ubiquitin-conjugating enzyme 2C; UBE2C), and type of chemotherapy (anthracycline-based chemotherapy with or without additional taxane; Supplementary Fig. S7C–S7G). Again, a comparison of the ability to predict response to chemotherapy based on logistic regression models yielded similar AUC values for IGKC and the 60-gene B-cell signature (Supplementary Fig. S8). In conclusion, IGKC showed strong correlation with survival, but also predicts chemosensitvity in ER-negative patients in the neoadjuvant setting.

**IGKC is also prognostic in NSCLC and colorectal cancer**

Because the immune response represents a general mechanism in tumor biology, we analyzed the prognostic impact of IGKC expression in lung, colorectal, and ovarian carcinomas (Supplementary Fig. S9). For lung cancer, we evaluated a novel cohort of 196 NSCLC patients from Uppsala. Both the B-cell metagene as well as single IGKC mRNA expression were significantly associated with longer survival in the univariate \( (P < 0.001) \) and multivariate Cox regression model \( (P = 0.032) \) adjusted to established clinical factors (Supplementary Fig. S9). Interestingly, Kaplan-Meier analysis in the subgroups revealed that this prognostic relevance was restricted to lung adenocarcinoma and was not seen in squamous lung carcinomas (Supplementary Fig. S9A and S9B), possibly because of the smaller sample size \( (n = 66) \). To further validate these results, we conducted a meta-analysis of publicly available Affymetrix data sets, including a total of 1,056 lung carcinomas (Fig. 3E and F). Both the univariate \( (P = 0.011; \text{ Fig. } 3E) \) and the bivariate meta-analysis, adjusted to the proliferation marker ubiquitin-conjugating enzyme 2C UBE2C \( (P = 0.015; \text{ Fig. } 3F) \), showed a significant association of IGKC with long-term overall survival.

Furthermore, we confirmed a significant association between IGKC and relapse-free survival in a meta-analysis of gene expression data of 513 patients with adenocarcinoma of the colorectum (Supplementary Fig. S9D). For overall survival, the association did not show significance (Supplementary Fig. S9E). No association was seen in a meta-analysis of 426 patients with ovarian cancer (Supplementary Fig. S9F).

**IGKC protein expression in archived breast cancer tissue**

Valuable biomarkers should be applicable for routine diagnostics. A major obstacle for gene expression studies is the limited availability of fresh tumor tissue in clinical practice. Indeed, most prognostic markers in breast cancer,
for example, ER, PR, HER2, and Ki-67, are routinely determined by immunohistochemistry. Therefore, we tested a monoclonal antibody against IGKC in FFPE tumor samples from the Mainz breast cancer cohort and found that IGKC was expressed in lymphoid cells in the tumor stroma of breast cancer (Fig. 5A). Immunostaining intensities correlated with IGKC RNA levels isolated from the tissue slides (P = 0.014; Jonckheere-terpstra test comparing staining intensity groups 0 vs. 1+ vs. 2+ vs. 3+) as well as with MFI (Fig. 5B).

**IGKC is expressed in tumor-infiltrating plasma cells**

Finally, to identify the cell type that was responsible for IGKC expression, we carried out costaining with antibodies against IGKC and either CD20 (a B-lymphocyte marker expressed in mature B cells but not on plasma cells), pan-cytokeratin (a marker for epithelial cells), or MUM1/IRF4 (a marker for activated B cells, plasmablasts, and plasma cells). No colocalization between IGKC and CD20, or IGKC and cytokeratin was observed (Fig. 5C). However, more than 90% of all cells that stained positive for nuclear MUM1/IRF4 were also positive for cytoplasmic IGKC (Fig. 5C). In addition, costaining with anti-human IgG showed that IGKC is only expressed in IgG-positive cells. Collectively, our results indicate that IGKC is expressed in mature plasma cells.

**Discussion**

Here, we describe a B cell–related gene signature, best represented by IGKC, as a strong prognostic marker in human breast, lung, and colorectal adenocarcinomas. Tumor-infiltrating plasma cells were identified to be the source of IGKC expression, which supports the concept that the adaptive humoral immune response is responsible for this host-dependent protective effect.

Numerous studies have shown the association of infiltrating immune cells and prognosis and response to therapy in different cancer types. However, most often the clinical relevance was ascribed to the T-cell lineage, with predominance of CD8+ and CD45RO+ T lymphocytes in colorectal, lung, and ovarian cancer (22–25).
metagenes, in the natural course of medically untreated
gates the role of B and T cells, as typified by their respective
acterized recently. Our own group systematically investi-

<table>
<thead>
<tr>
<th>Table 1. IGKC is associated with MFI in 3 independent cohorts of systemically untreated node-negative breast cancer (combined Mainz, Rotterdam, and Transbig cohorts, n = 766): univariate Cox analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mainz cohort (n = 200)</strong></td>
</tr>
<tr>
<td>IGKC*</td>
</tr>
<tr>
<td>IGKC*</td>
</tr>
<tr>
<td>IGKC*</td>
</tr>
</tbody>
</table>

*IGKC was analyzed as a continuous variable.

The immune infiltrates in breast cancer have been charac-
terized recently. Our own group systematically investi-
gates the role of B and T cells, as typified by their respective
metagenes, in the natural course of medically untreated
node-negative breast cancer (15). Our description of a
strong and independent prognostic impact of the humoral
immune system in rapidly proliferating node-negative
breast cancer was now confirmed by Bianchini and collea-
gues (26). Our study presents a consequent extension of the
previous work with focus of B-cell lineage and a systematic
implementation of solid biostatistics; therewith, we were
able to condense the 60-gene B-cell signature to IGKC as a
single gene. In addition to the prognostic impact, IGKC
expression predicts also response to neoadjuvant chemoo-
therapy in breast cancer. This further substantiates the
hypothesis that chemotherapy does not only exert a direct
cytotoxic effect but at the same time enhances the antitumor
immune response (27, 28).

The robust reproduction of IGKC’s clinical relevance in
other cancer types represents in general one of the sparse
exception that gene signatures are compatible between
different cancer types. Mainly proliferation-related sig-
natures have been shown to be transferable (29). Likewise the
immunohistochemical analysis of the proliferation marker
Ki-67 is of clinical importance in a variety of cancer entities.
(30). In near analogy, the B-cell metagene reflects a general
beneficial biological mechanism, which can easily be mea-
sured by IGKC protein staining. The validation of the gene
expression findings in 330 node-negative FFPE tumors by
immunohistochemistry was therefore of particular impor-
tance because fresh-frozen tissue is logistically demanding
to obtain on a routine basis and often only small biopsies
are available. Thus, an antibody-based detection of IGKC
is applicable in routine cancer diagnostics.

Our finding that IGKC in tumors arises from plasma cells
contradicts the provocative assumption that tumor cells are
capable of producing immunoglobulins to promote growth
and survival (31). Rather, it supports a previous report that
breast cancer specimens typically have tumor infiltration of
IgG-positive plasma cells (32). Similarly, another study of
Wang and colleagues described that the majority of tumor-
infiltrating plasma cells in invasive-ductal breast carcinomas
was of IgG isotype suggesting that a tumor-derived antigen
response may lead to the maturation of systemic B cells (33).
In accordance, in our study, costaining for IGKC and IgG
confirmed increased heavy class isotype switch to IgG. This
antigen-dependent switch from immunoglobulin M and
immunoglobulin D to IgG1 production is a well-known
feature of B-cell maturation (34) and plasma cell

<table>
<thead>
<tr>
<th>Table 2. Multivariate Cox analysis adjusted to established clinical factors (combined Mainz and Transbig cohorts, n = 480)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P</strong></td>
</tr>
<tr>
<td>Age (&lt;50 vs. &gt;50 y)</td>
</tr>
<tr>
<td>pT stage (&lt;2 vs. ≥2 cm)</td>
</tr>
<tr>
<td>Histologic grade (grade 1 and 2 vs. grade 3)</td>
</tr>
<tr>
<td>ER and PR (negative vs. positive)</td>
</tr>
<tr>
<td>HER2 status (negative vs. positive)</td>
</tr>
<tr>
<td>IGKC (continuous variable)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 3. Prognostic relevance of IGKC determined by qRT-PCR in paraffin-embedded tumor tissue of patients (n = 330) with node-negative breast cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>P</strong></td>
</tr>
<tr>
<td>IGKC (continuous variable)</td>
</tr>
<tr>
<td>Multivariate Cox analysis of MFI adjusted to established clinical factors</td>
</tr>
<tr>
<td>Age (&lt;50 vs. &gt;50 y)</td>
</tr>
<tr>
<td>pT stage (&lt;2 vs. ≥2 cm)</td>
</tr>
<tr>
<td>Histologic grade (grade 3 vs. Grades 1 and 2)</td>
</tr>
<tr>
<td>ER and PR (negative vs. positive)</td>
</tr>
<tr>
<td>ERBB2 status (positive vs. negative)</td>
</tr>
<tr>
<td>IGKC (continuous variable)</td>
</tr>
</tbody>
</table>
differentiation (35) after antigen encounter. Notably, several reports have characterized oligoclonal expansion of B cells in breast cancer (36–40). But none of these groups have yet shown a robust clinical impact of these intriguing findings.

Interestingly, the impact of the peritumoral immune system could be shown in other tumor entities, that is, in NSCLC and colorectal cancer, but not in ovarian cancer. We speculate that this may be explained by distinct growth pattern in different organs and subsequent different immunogenic properties. The biological roles of the IGKC signature have to be addressed in further studies. Nevertheless, the strong prognostic impact shared by breast, lung, and colorectal adenocarcinomas represents, to the best of our knowledge, the first robust comprehensive biomarker predicting the response of the immune system in a variety of cancer types.

We have to acknowledge the retrospective nature of our study, but currently prospective analyses of breast cancer without adjuvant treatment are not feasible considering current treatment recommendations (41). Also, a detailed evaluation of additional malignant tumor types is difficult because of limited clinical and pathologic data in the published expression array data sets. It should be considered that not only κ but also λ light chain–associated probe sets are among the top genes indicating an antitumor response (Supplementary Fig. S11). However, IGKC combines the advantages of not only belonging to the top genes indicating a favorable prognosis but also offers the possibility that RNA from paraffin tissue can be used, and the results could be validated by immunostaining with commercially available antibodies.

The novelty of our study is (i) the translation of our B-cell metagene approach (15) to other tumor types, (ii) the validation by independent methods, and (iii) the establishment of IGKC as a biomarker for clinical diagnostics on FFPE tissues. In conclusion, our findings strongly support the emerging role of the immune system as a clinically relevant hallmark of cancer biology (42).

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
The authors thank Ms. Seehase for her most competent support with data processing and statistical analyses and Mrs. Holzer as well as Mrs. Pfeiffer for excellent technical assistance. Dr. Simon Elkan, Michael Bergkvist, and Kristina Lamberg helped to establish the Uppsala lung cancer cohort. The authors also thank Dr. Friedrich Kommos for helpful discussion and Ms. Susanne Lindemann for valuable bibliographic support.

Grant Support
The study was supported by the Federal Ministry of Education and Research (BMBF, NGFN project Oncoprofile), the Swedish Cancer foundation, the Uppsala Lions Cancer foundation, and by the German Research Council (DFG, contract numbers RA 870/4-1 and RA 870/5-1).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 14, 2011; revised January 17, 2012; accepted February 3, 2012; published OnlineFirst February 20, 2012.

References


www.aacrjournals.org Clin Cancer Res; 18(9) May 1, 2012 2703

Published OnlineFirst February 20, 2012; DOI: 10.1158/1078-0432.CCR-11-2210

Downloaded from clinicancercases.aacrjournals.org on April 15, 2017. © 2012 American Association for Cancer Research.
A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors

Marcus Schmidt, Birte Hellwig, Seddik Hammad, et al.


Updated version
Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-11-2210

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2012/02/20/1078-0432.CCR-11-2210.DC1
http://clincancerres.aacrjournals.org/content/suppl/2012/04/25/1078-0432.CCR-11-2210.DC2

Cited articles
This article cites 42 articles, 22 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/18/9/2695.full.html#ref-list-1

Citing articles
This article has been cited by 24 HighWire-hosted articles. Access the articles at:
/content/18/9/2695.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.